NCT05371379View on ClinicalTrials.gov

Multiple Ascending Dose Study of CM338 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

November 4, 2022

Study Completion Date

November 4, 2022

Conditions
Healthy Subjects
Interventions
BIOLOGICAL

CM338 Injection

A humanized monoclonal antibody.

Trial Locations (1)

Unknown

PKUCare Luzhong Hospital, Zibo

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05371379 - Multiple Ascending Dose Study of CM338 in Healthy Volunteers | Biotech Hunter | Biotech Hunter